U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula CO3.Cu
Molecular Weight 123.555
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CUPRIC CARBONATE

SMILES

[Cu++].[O-]C([O-])=O

InChI

InChIKey=GEZOTWYUIKXWOA-UHFFFAOYSA-L
InChI=1S/CH2O3.Cu/c2-1(3)4;/h(H2,2,3,4);/q;+2/p-2

HIDE SMILES / InChI
Molecular Formula Cu
Molecular Weight 63.546
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula CO3
Molecular Weight 60.0089
Charge -2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a84d61a4-8e7f-4be1-aba6-f633b334aafc | http://www.sciencedirect.com/science/article/pii/S0167488912000158https://www.ncbi.nlm.nih.gov/pubmed/16971307DOI: 10.1107/s0567740869001725 Retrived from http://scripts.iucr.org/cgi-bin/paper?S0567740869001725https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=522.518 | http://www.worldofchemicals.com/chemicals/chemical-properties/cupric-glycinate.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/8556785 | https://www.ncbi.nlm.nih.gov/pubmed/2135524https://www.ncbi.nlm.nih.gov/pubmed/15704330 | https://www.ncbi.nlm.nih.gov/pubmed/12425037 | https://www.ncbi.nlm.nih.gov/pubmed/1599240 | http://www.certisusa.com/pdf-labels/Kocide3000_label.pdf | http://www.pesticideinfo.org/Detail_Chemical.jsp?Rec_Id=PC33524http://www.emdmillipore.com/US/en/product/Copper-di-ammonium-Titriplex-solution,MDA_CHEM-105217http://www.drugfuture.com/chemdata/tetraamminecopper-sulfate.html | https://cameochemicals.noaa.gov/chemical/3026https://www3.epa.gov/pesticides/chem_search/ppls/019713-00509-20110705.pdfhttp://fs1.agrian.com/pdfs/CORE_7.5_Copper_EDTA_Label.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/6526221http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500013010.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/24106015 | https://www.ncbi.nlm.nih.gov/pubmed/20942456http://www.drugfuture.com/chemdata/schweizer-s-reagent.html | http://pubs.acs.org/doi/abs/10.1021/ed062p878?journalCode=jceda8 | http://pubs.acs.org/doi/abs/10.1021/ed019p356
Curator's Comment: description was created based on several sources, including https://www.copper.org/resources/properties/compounds/other_compounds.html | http://www.vitamins-supplements.org/dietary-minerals/copper.php | https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bea888b4-9cc6-49da-89e6-5c273b974ed1

Tetraamminecopper dihydroxide also known as Schweizer's Reagent dissolves cellulose; used in rayon production.

CNS Activity

CNS Active
3913
Curator's Comment: Known to be CNS active in zebrafish. Human data not available.

Originator

Schweizer, J.
35
Sources: http://pubs.acs.org/doi/abs/10.1021/ja01512a012Schweizer, J. Prakt. Chem. 72, 109, 344 (1857).
Curator's Comment: http://www.drugfuture.com/chemdata/schweizer-s-reagent.html

Approval Year

1921
1467
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 3.42 µM [Ki]
Ceruloplasmin
35
Target ID: P00450
Gene ID: 1356.0
Gene Symbol: CP
Target Organism: Homo sapiens (Human)
Binding Agent
1064
Glutathione S-transferase, rat, liver
35
Target ID: Glutathione S-transferase, rat, liver
Binding Agent
1064
Modulator
828
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Preclinical
Unknown

Approved Use

Unknown
Preventing
Preclinical
Unknown

Approved Use

Unknown
Preventing
Approved
8429
Cupric glycinate

Approved Use

Indications for use. For beef calves and beef cattle for the prevention of copper deficiency, or when labeled for veterinary prescription use, for the prevention and/or treatment of copper deficiency alone or in association with molybdenum toxicity.
Primary
Approved
8429
COPPER•MAX

Approved Use

Unknown
Primary
Not Provided
504
Unknown

Approved Use

Unknown
Preventing
Preclinical
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
Diagnostic
Preclinical
Unknown

Approved Use

Unknown
Preventing
Approved
8429
COPPER

Approved Use

Copper 0.4 mg/mL (Cupric Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN). Administration helps to maintain copper serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
Preventing
Approved
8429
COPINOX

Approved Use

Copinox 4g is indicated for the prevention and treatment of copper deficiency in cattle and sheep.
PubMed

PubMed

TitleDatePubMed
Determination of protein by the biuret reaction using cupric hydroxide suspension reagent.
1960
The effect of various fluoride compounds on the development of experimental root surface caries in hamsters.
1995 Dec
Cardiopulmonary events during hemodialysis: effects of dialysis membranes and dialysate buffers.
2000 Jul
The effectiveness of ecologically acceptable ways of protection of field-grown tomato (Lycopersicon lycopersicum (L.) Karsten) from tomato late blight (Phytophthora infestans (Mont.) de Bary) in extreme weather conditions.
2001
Antioxidant activity of olive pulp and olive oil phenolic compounds of the arbequina cultivar.
2005 Mar 23
Cu(II) acetate- and Mn(III) acetate-mediated radical reactions of [60]fullerene with ketonic compounds.
2005 Mar 7
X-ray absorption spectroscopy study of a copper-containing material after thermal treatment.
2006 Apr 17
A spectroscopic and thermoanalytical study of the mineral hoganite.
2007 May
Enhanced copper release from pipes by alternating stagnation and flow events.
2007 Nov 1
Copper(II) acetate-catalyzed addition of arylboronic acids to aromatic aldehydes.
2009 Jan 16
Generation of oxidant response to copper and iron nanoparticles and salts: Stimulation by ascorbate.
2009 Oct 30
Copper-promoted coupling of vinyl boronates and alcohols: a mild synthesis of allyl vinyl ethers.
2010 Feb 3
Regulation of plasminogen activator inhibitor-1 expression in endothelial cells with exposure to metal nanoparticles.
2010 May 19
A chelator-free multifunctional [64Cu]CuS nanoparticle platform for simultaneous micro-PET/CT imaging and photothermal ablation therapy.
2010 Nov 3
Anti-ovulatory activity of H2 receptor blockers in albino rabbits--a preliminary study.
2011 Apr
Rapid free chlorine decay in the presence of Cu(OH)2: chemistry and practical implications.
2011 Oct 15
CuBr2--a new multiferroic material with high critical temperature.
2012 May 8
Probing the chemical nature of dihydrogen complexation to transition metals, a gas phase case study: H2-CuF.
2013 Jan 18
Design, synthesis, antioxidant, and anti-breast cancer activities of novel diethyl(alkyl/aryl/heteroarylamino)(4-(pyridin-2-yl)phenyl)methylphosphonates.
2013 May
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.
2013 Nov 25
The modality of cell-particle interactions drives the toxicity of nanosized CuO and TiO₂ in human alveolar epithelial cells.
2013 Oct 24
SILAC-based quantitative proteomic analysis of human lung cell response to copper oxide nanoparticles.
2014
Interference of CuO nanoparticles with metal homeostasis in hepatocytes under sub-toxic conditions.
2014
Synthesis and biomedical applications of copper sulfide nanoparticles: from sensors to theranostics.
2014 Feb 26
Effects of different sources of copper on Ctr1, ATP7A, ATP7B, MT and DMT1 protein and gene expression in Caco-2 cells.
2014 Jul
CuO nanoparticles induce apoptosis by impairing the antioxidant defense and detoxification systems in the mouse hippocampal HT22 cell line: protective effect of crocetin.
2015 Jun
Dissecting copper homeostasis in diabetes mellitus.
2017 Apr
Unusual 4-arsonoanilinium cationic species in the hydrochloride salt of (4-aminophenyl)arsonic acid and formed in the reaction of the acid with copper(II) sulfate, copper(II) chloride and cadmium chloride.
2017 Apr 1
Roles of Copper-Binding Proteins in Breast Cancer.
2017 Apr 20
Supplementation with copper edetate in control of Haemonchus contortus of sheep, and its effect on cholinesterase's and superoxide dismutase activities.
2017 Feb
Ultrasonic energy enhanced the efficiency of advance extraction methodology for enrichment of trace level of copper in serum samples of patients having neurological disorders.
2017 Jul
Comparison of the efficacy of a commercial footbath product with copper sulfate for the control of digital dermatitis.
2017 Jul
Folic acid-modified and functionalized CuS nanocrystal-based nanoparticles for combined tumor chemo- and photothermal therapy.
2017 Jun
Amino acid-mediated 'turn-off/turn-on' nanozyme activity of gold nanoclusters for sensitive and selective detection of copper ions and histidine.
2017 Jun 15
Effects of Excess Copper Ions on Decidualization of Human Endometrial Stromal Cells.
2017 May
Patents

Patents

04904671
36
05034547
35
06203724
35
07465750
39
08399460
35
08722671
35
US2006191376
35
US20090239073 A1
35
US20090269269
35
US20160374209
35
US2046937 A
35
US2460067 A
35
US2533245 A
35
US3900504 A
35
US4020180 A
35
US6579328
35
US6670494
35
US7053251 B2
35
US7402296
35
US8921591
35
WO2003052039A1
35
WO2014001924A1
35
WO2017019802A1
35
WO9806419
35

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Veterinary drug
Copper 0.4 mg/mL (Cupric Chloride Injection) contains 0.4 mg copper/mL and is administered intravenously only after dilution. The additive should be diluted in a volume of fluid not less than 100 mL. For the adult receiving total parenteral nutrition, the suggested additive dosage is 0.5 to 1.5 mg copper/day (1.25 to 3.75 mL/day). For pediatric patients, the suggested additive dosage is 20 mcg copper/kg/day (0.05 mL/kg/day). Infants weighing less than 1500 gm may have increased requirements because of their low body reserves and increased requirements for growth.
Route of Administration: Intravenous
In Vitro Use Guide
Human Endometrial Stromal Cells were treated with non-toxic concentrations of copper ions (0-250 uM). mRNA expressions of insulin-like growth factor binding protein (IGFBP-1), prolactin (PRL), Mn-SOD, and FOXO1 were down-regulated during decidualization following the treatments with 100 or 250 uM copper ions. Meanwhile, the amount of malonaldehyde in the supernatant of cells was increased.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:57:53 UTC 2023
Edited
by admin
on Fri Dec 15 16:57:53 UTC 2023
Record UNII
9AOA5F11GJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CUPRIC CARBONATE
Common Name English
CUPROMAAG
Brand Name English
COPPER MONOCARBONATE
Systematic Name English
COPPER CARBONATE (1:1)
Systematic Name English
CARBONIC ACID, COPPER SALT
Common Name English
COPPER(II) CARBONATE
HSDB  
Systematic Name English
CARBONIC ACID, COPPER(2+) SALT (1:1)
Common Name English
COPPER (AS CARBONATE)
Common Name English
COPPER(II) CARBONATE [HSDB]
Common Name English
COPPER CARBONATE
Systematic Name English
Code System Code Type Description
PUBCHEM
14452
Created by admin on Fri Dec 15 16:57:53 UTC 2023 , Edited by admin on Fri Dec 15 16:57:53 UTC 2023
PRIMARY
FDA UNII
9AOA5F11GJ
Created by admin on Fri Dec 15 16:57:53 UTC 2023 , Edited by admin on Fri Dec 15 16:57:53 UTC 2023
PRIMARY
ECHA (EC/EINECS)
214-671-4
Created by admin on Fri Dec 15 16:57:53 UTC 2023 , Edited by admin on Fri Dec 15 16:57:53 UTC 2023
PRIMARY
WIKIPEDIA
COPPER(II) CARBONATE
Created by admin on Fri Dec 15 16:57:53 UTC 2023 , Edited by admin on Fri Dec 15 16:57:53 UTC 2023
PRIMARY
CAS
7492-68-4
Created by admin on Fri Dec 15 16:57:53 UTC 2023 , Edited by admin on Fri Dec 15 16:57:53 UTC 2023
NON-SPECIFIC STOICHIOMETRY
SMS_ID
100000156471
Created by admin on Fri Dec 15 16:57:53 UTC 2023 , Edited by admin on Fri Dec 15 16:57:53 UTC 2023
PRIMARY
CAS
1184-64-1
Created by admin on Fri Dec 15 16:57:53 UTC 2023 , Edited by admin on Fri Dec 15 16:57:53 UTC 2023
PRIMARY
HSDB
258
Created by admin on Fri Dec 15 16:57:53 UTC 2023 , Edited by admin on Fri Dec 15 16:57:53 UTC 2023
PRIMARY
EPA CompTox
DTXSID6034471
Created by admin on Fri Dec 15 16:57:53 UTC 2023 , Edited by admin on Fri Dec 15 16:57:53 UTC 2023
PRIMARY
DAILYMED
9AOA5F11GJ
Created by admin on Fri Dec 15 16:57:53 UTC 2023 , Edited by admin on Fri Dec 15 16:57:53 UTC 2023
PRIMARY
RXCUI
1427055
Created by admin on Fri Dec 15 16:57:53 UTC 2023 , Edited by admin on Fri Dec 15 16:57:53 UTC 2023
PRIMARY RxNorm
EVMPD
SUB130387
Created by admin on Fri Dec 15 16:57:53 UTC 2023 , Edited by admin on Fri Dec 15 16:57:53 UTC 2023
PRIMARY
MESH
C086270
Created by admin on Fri Dec 15 16:57:53 UTC 2023 , Edited by admin on Fri Dec 15 16:57:53 UTC 2023
PRIMARY
Related Record Type Details
Structure of CUPRIC CATION
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of CUPRIC CATION
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966